Stay updated on Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial

Sign up to get notified when there's something new on the Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating an update in the dosage of mepolizumab (a-IL-5 antibody) being administered in the clinical trial for patients with bullous pemphigoid.
    Difference
    0.1%
    Check dated 2024-06-06T14:30:08.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying inclusion and exclusion criteria for men and women over 18 years with active bullous pemphigoid. Previously, this section only indicated that no information was provided about collaborators.
    Difference
    14%
    Check dated 2024-05-22T21:03:01.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:35:36.000Z thumbnail image

Stay in the know with updates to Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Anti-IL-5 Therapy in Bullous Pemphigoid Clinical Trial page.